SCHEMBL1020162

SCHEMBL1020162

COc1ccc(Cc2nsc(N(C)CCN(C)S(=O)(=O)c3ccc(OC)cc3)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 1/20 0.40
BMP1 P13497 2/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 2/20 0.38
PDE4D Q08499 2/20 0.38
TAS2R14 Q9NYV8 2/20 0.37
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
MMP1 P03956 1/20 0.36
MMP9 P14780 1/20 0.36
MMP13 P45452 1/20 0.36
ADAM17 P78536 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2007365 0.96 LMNA (0.45) LMNATSHRHTTRECQLSMN1; SMN2
SCHEMBL2003100 0.95 CNR2 (0.41) NOS2SMN1; SMN2ALDH1A1MAPTMMP9
SCHEMBL2012105 0.95 TAS2R14 (0.41) NOS2BMP1LMNASMN1; SMN2ALDH1A1
SCHEMBL1022400 0.95 ALDH1A1 (0.40) BMP1LMNATSHRHTTALDH1A1
SCHEMBL1020526 0.90 BMP1 (0.41) BMP1LMNASMN1; SMN2ALDH1A1PDE4D
SCHEMBL1019577 0.89 ALDH1A1 (0.38) NOS2BMP1LMNATSHRHTT
SCHEMBL2005838 0.88 MAPT (0.46) LMNATSHRHTTRECQLSMN1; SMN2
SCHEMBL2002634 0.88 MGAT3 (0.42) BMP1SMN1; SMN2ALDH1A1PDE4DKDM4E
SCHEMBL1021067 0.86 TAS2R14 (0.40) LMNATSHRHTTRECQLSMN1; SMN2
SCHEMBL1018717 0.86 RAB9A (0.44) LMNATSHRHTTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP NOS2 3358/4885BMP1 4124/4885LMNA 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.